INmune Bio pivots to CORDStrom: regulatory derisking and a 97% tape move
Q2 delivery across manufacturing, MHRA alignment, and a clear path to MAA/BLA flips the narrative from pipeline breadth to near-term commercialization.
INMB · Earnings Call · 2026-08-06
Execution trumps pipeline breadth
INmune Bio's (INMB) Q2 2026 call was a study in focus. Two late-stage platforms exist, but the company's energy is now squarely on CORDStrom platform–derived Ebstracel for recessive dystrophic epidermolysis bullosa (RDEB). Management secured formal MHRA alignment, won the pediatric investigation plan, and completed a commercial manufacturing milestone. "We now expect to submit the Ebstracel MAA by the end of Q3 or early Q4 2026," “CEO David Moss stated, adding that the application will seek conditional marketing authorization in RDEB” — David J. Moss, Chief Executive Officer · 2026-08-06. The tape has already voted: the stock is up 97% over the past 90 trading days (company_tape recent_90d: ret=+96.6%, up-17w:+97%). That move follows a brutal drawdown from the 2021 peak (dd=-91.7%), suggesting the market is finally pricing in the CORDStrom inflection rather than the Alzheimer's story, which had been the company's primary narrative for years.Regulatory and manufacturing derisking
Chief Scientific Officer Mark Lowdell detailed the derisking at the CMC and regulatory levels. The MHRA's official minutes from the pre-MAA scientific advice meeting "confirmed their alignment across every question that we submitted covering CMC, nonclinical, and clinical matters," and the agency recognized the MISSION EB data as demonstrating clinically meaningful benefit, particularly in pain and pruritus. On the manufacturing front, the first commercial-compliant cord tissue was processed at the Cell and Gene Therapy Catapult in Stevenage, and the MSC isolation stage was transferred to the intended commercial facility. "Combined with our expanded Anthony Nolan agreement, this gives us a scalable supply foundation designed to support UK, EU, and US filings and future commercial supply," he noted. This is a marked contrast to prior quarters, where the FDA's donor-testing requirements for U.S. submissions were a documented hurdle. In the March 2026 call, Lowdell explained that U.K. donors would need to be tested in U.S. accredited labs, requiring a new master seedstock. Now, with the commercial manufacturing infrastructure in place and the platform patent entering the U.S. national phase, the company appears to have cleared that logjam. The newly formed Scientific Advisory Board will also prioritize potency assays and phase 3 design, further closing the manufacturing-consistency gap that has plagued other MSC programs.XPro: secondary but not sidelined
While CORDStrom takes the spotlight, XPro (the Alzheimer's candidate) received FDA Fast Track designation and posted a statistically significant effect on white-matter myelin MRI biomarkers (p=0.0028, Cohen's d=0.46). The phase 2 MINDFuL results were published in npj Dementia. Management continues to evaluate strategic partnerships, but the emphasis is clearly on preserving optionality. "The peer-reviewed report showed directionally consistent benefit across clinical and biomarker endpoints in the prespecified inflammation-rich subgroup," Moss said. The company's prior calls were dominated by XPro's endpoint debates (EMAC vs. CDR) and partnership timelines; this quarter those topics were relegated to a brief mention, signaling a deliberate strategic reprioritization.Capital discipline and the PRV optionality
The financial picture is tight but improving. Net loss was $1.3M in Q2, helped by a $800K R&D benefit from Australian rebates, and cash stood at $18.4M with a subsequent $4.2M rebate received. CFO Cory Ellspermann guided to a burn rate of $1–1.5M per month, extending the runway into Q2 2027. Cash runway (quarters) improved to 6.3x from a 1.89x trough in Q4 2024. The most striking piece of the capital narrative is the priority review voucher (PRV). Ebstracel holds orphan drug and rare pediatric disease designations, the latter entitling the company to a PRV upon U.S. approval. "The last few went for between $150 to around $200 million," Moss said. That alone exceeds the company's current market cap (roughly $37M). The CEO was uncharacteristically blunt about the mismatch:That comment anchors the valuation discussion. Even after the 97% run, the market is pricing INMB as a story stock with a binary outcome, yet the regulatory path to conditional approval in the U.K. is now well-articulated, the commercial manufacturing is derisked, and the PRV provides non-dilutive capital optionality. The open-label confirmatory trial (40–45 patients, 18 months) is set to read out in mid-2028, but the MAA itself is expected to be submitted by early Q4 2026 — a near-term catalyst. The company's burn rate discipline is another departure. Moss emphasized that they are "very judicious" about spending and dilution, a contrast to the pre-pivot era when R&D spending peaked at $10M/Q in 2024. Q2 R&D was a benefit of $0.8M thanks to rebates; the year-over-year decline is steep (-52%).In terms of value, I mean, just the PRV alone, obviously, is quite a bit larger than our current market cap. Really, what we do is we are just keeping our heads down.